LABELS · 09b23b47-fb31-434b-9ad5-9bae9303933b

Docetaxel

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-08-22
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive docetaxel as a single agent at a dose of 100 mg/m 2 [ see Warnings and Precautions (5.1) ] . Avoid the use of Docetaxel Injection in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 × ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel Injection [ see Warnings and Precautions (5.2) ]. Do not administer Docetaxel Injection to patients with neutrophil counts of <1500 cells/mm 3 . Monitor blood counts frequently as neutropenia may be severe and result in infection [ see Warnings and Precautions (5.3) ]. Do not administer Docetaxel Injection to patients who have a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80 [ see Contraindications (4) ]. Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel Injection infusion and administration of appropriate therapy [ see Warnings and Precautions (5.5) ]. Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [ see Warnings and Precautions (5.6) ]. WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning. • Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving docetaxel at 100 mg/m 2 ( 5.1 ) • Avoid use of Docetaxel Injection if bilirubin > ULN, or if AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle ( 5.2 ) • Do not administer Docetaxel Injection to patients with neutrophil counts <1500 cells/mm 3 . Obtain frequent blood counts to monitor for neutropenia ( 4 , 5.3 ) • Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of Docetaxel Injection and administration of appropriate therapy ( 5.5 ) • Contraindicated if history of severe hypersensitivity reactions to docetaxel or to drugs formulated with polysorbate 80 ( 4 ) • Severe fluid retention may occur despite dexamethasone ( 5.6 )

Indications and usage: exact source text

1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

Full extracted label fields

application numbers

NDA022234

boxed warning exact

WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION Treatment-related mortality associated with docetaxel is increased in patients with abnormal liver function, in patients receiving higher doses, and in patients with non-small cell lung carcinoma and a history of prior treatment with platinum-based chemotherapy who receive docetaxel as a single agent at a dose of 100 mg/m 2 [ see Warnings and Precautions (5.1) ] . Avoid the use of Docetaxel Injection in patients with bilirubin > upper limit of normal (ULN), or to patients with AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. Patients with elevations of bilirubin or abnormalities of transaminase concurrent with alkaline phosphatase are at increased risk for the development of severe neutropenia, febrile neutropenia, infections, severe thrombocytopenia, severe stomatitis, severe skin toxicity, and toxic death. Patients with isolated elevations of transaminase >1.5 × ULN also had a higher rate of febrile neutropenia. Measure bilirubin, AST or ALT, and alkaline phosphatase prior to each cycle of Docetaxel Injection [ see Warnings and Precautions (5.2) ]. Do not administer Docetaxel Injection to patients with neutrophil counts of <1500 cells/mm 3 . Monitor blood counts frequently as neutropenia may be severe and result in infection [ see Warnings and Precautions (5.3) ]. Do not administer Docetaxel Injection to patients who have a history of severe hypersensitivity reactions to docetaxel or to other drugs formulated with polysorbate 80 [ see Contraindications (4) ]. Severe hypersensitivity reactions have been reported in patients despite dexamethasone premedication. Hypersensitivity reactions require immediate discontinuation of the Docetaxel Injection infusion and administration of appropriate therapy [ see Warnings and Precautions (5.5) ]. Severe fluid retention occurred in 6.5% (6/92) of patients despite use of dexamethasone premedication. It was characterized by one or more of the following events: poorly tolerated peripheral edema, generalized edema, pleural effusion requiring urgent drainage, dyspnea at rest, cardiac tamponade, or pronounced abdominal distention (due to ascites) [ see Warnings and Precautions (5.6) ]. WARNING: TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION See full prescribing information for complete boxed warning. • Treatment-related mortality increases with abnormal liver function, at higher doses, and in patients with NSCLC and prior platinum-based therapy receiving docetaxel at 100 mg/m 2 ( 5.1 ) • Avoid use of Docetaxel Injection if bilirubin > ULN, or if AST and/or ALT >1.5 × ULN concomitant with alkaline phosphatase >2.5 × ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle ( 5.2 ) • Do not administer Docetaxel Injection to patients with neutrophil counts <1500 cells/mm 3 . Obtain frequent blood counts to monitor for neutropenia ( 4 , 5.3 ) • Severe hypersensitivity, including fatal anaphylaxis, has been reported in patients who received dexamethasone premedication. Severe reactions require immediate discontinuation of Docetaxel Injection and administration of appropriate therapy ( 5.5 ) • Contraindicated if history of severe hypersensitivity reactions to docetaxel or to drugs formulated with polysorbate 80 ( 4 ) • Severe fluid retention may occur despite dexamethasone ( 5.6 )

brand names

Docetaxel

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0ec4bcc-93ea-4c41-a4b6-95ec19491807

generic names

DOCETAXEL ANHYDROUS

09b23b47-fb31-434b-9ad5-9bae9303933b

indications and usage exact

1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).

indications and usage tables exact

is original packager

true

manufacturer names

Hospira, Inc.

matched search terms

cancer
carcinoma

package ndcs

0409-0201-02
0409-0201-10
0409-0201-20

product ndcs

0409-0201

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

INTRAVENOUS

rxcuis

1093280
1860619

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

NDA022234

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 285
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 0

current approval status

not_reconciled

duplicate text group

dup-36a9a7f54b5576ca37ae

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-f63512bf7775595dd6ce

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

end: 80
end exclusive: true
exact text: is a microtubule inhibitor indicated
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 44

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 85
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for:
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · unclassified context

application numbers

NDA022234

brand names

Docetaxel

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 487
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Docetaxel Injection is a microtubule inhibitor indicated for: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreat
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 0

current approval status

not_reconciled

duplicate text group

dup-7df7b101ae9b7acc3237

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-acbad5560f86e3b65765

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

Source null

qualifier mentions

context exact
• Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant trea
kind
biomarker
polarity
not_inferred
span
end
185
end exclusive
true
exact text
metastatic BC after chemotherapy failure
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
145
context exact
• Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adju
kind
stage_or_setting
polarity
not_inferred
span
end
176
end exclusive
true
exact text
locally advanced or metastatic BC after chemotherap
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
125
context exact
erapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 )
kind
stage_or_setting
polarity
not_inferred
span
end
275
end exclusive
true
exact text
adjuvant treatment of operable node-positiv
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
232

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 287
end exclusive: true
exact text: • Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 )
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 86

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA022234

brand names

Docetaxel

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 703
end exclusive: true
exact text: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated,
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 88

current approval status

not_reconciled

duplicate text group

dup-ce3473841a7c31ac5c11

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-d710127b43feb66b12b7

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

Source null

qualifier mentions

context exact
l Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced
kind
biomarker
polarity
not_inferred
span
end
406
end exclusive
true
exact text
metastatic NSCLC after platinum therapy fai
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
363
context exact
e; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 )
kind
biomarker
polarity
not_inferred
span
end
499
end exclusive
true
exact text
metastatic untreated NSCLC ( 1
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
469
context exact
• Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, local
kind
stage_or_setting
polarity
not_inferred
span
end
394
end exclusive
true
exact text
locally advanced or metastatic NSCLC after platinum
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
343
context exact
SCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 )
kind
stage_or_setting
polarity
not_inferred
span
end
447
end exclusive
true
exact text
unresectable
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
435
context exact
tinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 )
kind
stage_or_setting
polarity
not_inferred
span
end
499
end exclusive
true
exact text
locally advanced or metastatic untreated NSCLC ( 1
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
449

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 503
end exclusive: true
exact text: • Non-small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 )
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 288

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA022234

brand names

Docetaxel

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 825
end exclusive: true
exact text: Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 304

current approval status

not_reconciled

duplicate text group

dup-c74dd4b0380519873192

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-f610f0e4618f4e4297db

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

Source null

qualifier mentions

context exact
ration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 )
kind
biomarker
polarity
not_inferred
span
end
613
end exclusive
true
exact text
metastatic castration-resistant prostate ca
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
570
context exact
ration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 )
kind
stage_or_setting
polarity
not_inferred
span
end
615
end exclusive
true
exact text
metastatic castration-resistant prostate canc
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
570

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 625
end exclusive: true
exact text: • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 )
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 504

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · unclassified context

application numbers

NDA022234

brand names

Docetaxel

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 964
end exclusive: true
exact text: atin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) • Castration-Resistant Prostate Cancer (CRPC): with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated fo
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 426

current approval status

not_reconciled

duplicate text group

dup-bf3039747b91c4d7a28d

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-c5cc96567c2be01def49

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

Source null

qualifier mentions

context exact
cinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 )
kind
stage_or_setting
polarity
not_inferred
span
end
715
end exclusive
true
exact text
advanced GC
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
704

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 764
end exclusive: true
exact text: • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 )
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 626

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA022234

brand names

Docetaxel

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1110
end exclusive: true
exact text: e in metastatic castration-resistant prostate cancer ( 1.3 ) • Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combinat
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 565

current approval status

not_reconciled

duplicate text group

dup-b13bd404fe1ae699540f

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-26b9c8192a4678d7ce56

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

Source null

qualifier mentions

context exact
with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )
kind
stage_or_setting
polarity
not_inferred
span
end
906
end exclusive
true
exact text
locally advanced SCCHN ( 1
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
880

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 910
end exclusive: true
exact text: • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 765

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · positive indication candidate

application numbers

NDA022234

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1278
end exclusive: true
exact text: d GC, including the gastroesophageal junction ( 1.4 ) • Squamous Cell Carcinoma of the Head and Neck (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 711

current approval status

not_reconciled

duplicate text group

dup-39acc6be0914256871ac

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-8580b9709c4f75928351

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

end: 961
end exclusive: true
exact text: is indicated
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 949

qualifier mentions

context exact
ated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
1060
end exclusive
true
exact text
metastatic breast cancer after failure of p
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1017
context exact
l Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1048
end exclusive
true
exact text
locally advanced or metastatic breast cancer after
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
997

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 1078
end exclusive: true
exact text: 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 911

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 8 · positive indication candidate

application numbers

NDA022234

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1446
end exclusive: true
exact text: locally advanced SCCHN ( 1.5 ) 1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior p
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 879

current approval status

not_reconciled

duplicate text group

dup-cb92203df86711558796

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-ee23df16e530e376ad16

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

end: 1164
end exclusive: true
exact text: is indicated
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1152

qualifier mentions

context exact
with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
kind
stage_or_setting
polarity
not_inferred
span
end
1216
end exclusive
true
exact text
adjuvant treatment of patients with operabl
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1173
context exact
Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
kind
regimen
polarity
not_inferred
span
end
1245
end exclusive
true
exact text
in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1099

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 1246
end exclusive: true
exact text: Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1079

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · positive indication candidate

application numbers

NDA022234

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1673
end exclusive: true
exact text: failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously recei
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1047

current approval status

not_reconciled

duplicate text group

dup-2339a027edaf5d92cd35

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-6b6ddcda3c802a034257

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

end: 1328
end exclusive: true
exact text: is indicated
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1316

qualifier mentions

context exact
ated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
biomarker
polarity
not_inferred
span
end
1427
end exclusive
true
exact text
metastatic non-small cell lung cancer after
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1384
context exact
ingle agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1415
end exclusive
true
exact text
locally advanced or metastatic non-small cell lung
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1364
context exact
1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
kind
regimen
polarity
not_inferred
span
end
1472
end exclusive
true
exact text
as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1298

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 1473
end exclusive: true
exact text: 1.2 Non-small Cell Lung Cancer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy.
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1247

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 10 · positive indication candidate

application numbers

NDA022234

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1909
end exclusive: true
exact text: cer Docetaxel Injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Doce
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1274

current approval status

not_reconciled

duplicate text group

dup-00e9dc730654c7b12a7a

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-7efe51f6dc3deed83cb0

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

end: 1536
end exclusive: true
exact text: is indicated
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1524

qualifier mentions

context exact
reatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
kind
biomarker
polarity
not_inferred
span
end
1649
end exclusive
true
exact text
metastatic non-small cell lung cancer who h
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1606
context exact
h cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer
kind
stage_or_setting
polarity
not_inferred
span
end
1584
end exclusive
true
exact text
unresectable
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1572
context exact
indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for thi
kind
stage_or_setting
polarity
not_inferred
span
end
1637
end exclusive
true
exact text
locally advanced or metastatic non-small cell lung
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1586
context exact
Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
kind
regimen
polarity
not_inferred
span
end
1673
end exclusive
true
exact text
in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously recei
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1494

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 1709
end exclusive: true
exact text: Docetaxel Injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition.
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1474

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 11 · positive indication candidate

application numbers

NDA022234

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2077
end exclusive: true
exact text: ith cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1510

current approval status

not_reconciled

duplicate text group

dup-b148adfec8d4f5faef70

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-21429cacaed4277d38ab

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

end: 1793
end exclusive: true
exact text: is indicated
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1781

qualifier mentions

context exact
prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
biomarker
polarity
not_inferred
span
end
1872
end exclusive
true
exact text
metastatic castration-resistant prostate ca
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1829
context exact
prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
stage_or_setting
polarity
not_inferred
span
end
1874
end exclusive
true
exact text
metastatic castration-resistant prostate canc
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1829
context exact
1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
kind
regimen
polarity
not_inferred
span
end
1876
end exclusive
true
exact text
in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1750

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 1877
end exclusive: true
exact text: 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1710

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 12 · positive indication candidate

application numbers

NDA022234

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2374
end exclusive: true
exact text: hemotherapy for this condition. 1.3 Prostate Cancer Docetaxel Injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the h
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1678

current approval status

not_reconciled

duplicate text group

dup-5fa85a9b464cba5e46bc

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-3ba4f25f6f94bda833ba

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

end: 1984
end exclusive: true
exact text: is indicated
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1972

qualifier mentions

context exact
luorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction,
kind
stage_or_setting
polarity
not_inferred
span
end
2051
end exclusive
true
exact text
advanced gastric adenocarcinoma
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
2020
context exact
geal junction, who have not received prior chemotherapy for advanced disease.
kind
stage_or_setting
polarity
not_inferred
span
end
2173
end exclusive
true
exact text
advanced disease
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
2157
context exact
1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advance
kind
regimen
polarity
not_inferred
span
end
2104
end exclusive
true
exact text
in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal ju
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
1925

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 2174
end exclusive: true
exact text: 1.4 Gastric Adenocarcinoma Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1878

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 13 · positive indication candidate

application numbers

NDA022234

brand names

Docetaxel

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2395
end exclusive: true
exact text: indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 1975

current approval status

not_reconciled

duplicate text group

dup-53f29b7d69863ba442c1

extraction review status

automated_candidate_pending_source_review

generic names

DOCETAXEL ANHYDROUS

ind-span-722b43488e28ac9c44d4

label id

09b23b47-fb31-434b-9ad5-9bae9303933b

positive predicate support span

end: 2279
end exclusive: true
exact text: is indicated
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 2267

qualifier mentions

context exact
l is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
kind
stage_or_setting
polarity
not_inferred
span
end
2376
end exclusive
true
exact text
locally advanced squamous cell carcinoma of the hea
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
2325
context exact
1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
kind
regimen
polarity
not_inferred
span
end
2394
end exclusive
true
exact text
in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
2220

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

abbreviation
NSCLC
definition exact
Non-small Cell Lung Cancer
definition span
end
324
end exclusive
true
exact text
Non-small Cell Lung Cancer (NSCLC)
label id
09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start
290

source span

end: 2395
end exclusive: true
exact text: 1.5 Head and Neck Cancer Docetaxel Injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
label id: 09b23b47-fb31-434b-9ad5-9bae9303933b
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: cad2ca433b82c09f9ab87da38956f4ee855605e0dbb28aa815e93c70dddbec96
start: 2175

source url

https://api.fda.gov/drug/label.json?search=id%3A%2209b23b47-fb31-434b-9ad5-9bae9303933b%22

spl effective date

2024-08-22

spl set id

a0ec4bcc-93ea-4c41-a4b6-95ec19491807

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice